Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Gilead and Spring Bank study HBV combo therapy in trial collaboration

Executive Summary

Gilead Sciences Inc. and Spring Bank Pharmaceuticals Inc. agreed to conduct a Phase II trial investigating the combination of Gilead's Viread (tenofovir) with Spring Bank's SB9200 for hepatitis B virus.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Trial Collaborations
    • R&D (No Licensing)

Related Companies

UsernamePublicRestriction

Register